These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 18030581

  • 1. Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin's lymphoma.
    Kita T, Watanabe S, Yano F, Hayashi K, Yamamoto M, Iwasaki Y, Kosuda S.
    Ann Nucl Med; 2007 Nov; 21(9):499-503. PubMed ID: 18030581
    [Abstract] [Full Text] [Related]

  • 2. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y, Tsurumi H, Sawada M, Yamada T, Hara T, Fukuno K, Goto H, Moriwaki H.
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [Abstract] [Full Text] [Related]

  • 3. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin's lymphoma.
    Jo SA, Hwang SH, Chang CL, Kim SY, Shin HJ, Chung JS, Sol MY, Lee EY.
    Korean J Lab Med; 2010 Dec; 30(6):600-5. PubMed ID: 21157146
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
    Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G, Tura S.
    Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
    [Abstract] [Full Text] [Related]

  • 5. Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma.
    Toji T, Takata K, Sato Y, Miyata-Takata T, Hayashi E, Habara T, Maeda Y, Tanimoto M, Yoshino T.
    J Clin Pathol; 2015 Aug; 68(8):622-7. PubMed ID: 25935549
    [Abstract] [Full Text] [Related]

  • 6. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
    Setoyama Y, Imai J, Ishikawa T, Sakaida H, Takaori-Kondo A, Kawamata S, Uchiyama T.
    Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
    [Abstract] [Full Text] [Related]

  • 7. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
    Stasi R, Zinzani L, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Tura S, Papa G.
    Cancer; 1994 Sep 15; 74(6):1792-800. PubMed ID: 8082082
    [Abstract] [Full Text] [Related]

  • 8. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY, Kao A, Yen RF.
    Oncol Rep; 2002 Sep 15; 9(2):321-5. PubMed ID: 11836600
    [Abstract] [Full Text] [Related]

  • 9. Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma.
    Fujimura K, Ebinuma H, Fukamachi I, Ohwada C, Kawaguchi T, Shimizu N, Takeuchi M, Sakaida E, Jiang M, Nakaseko C, Bujo H.
    Clin Chim Acta; 2014 Mar 20; 430():48-54. PubMed ID: 24394293
    [Abstract] [Full Text] [Related]

  • 10. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, Okuno M, Takami T, Seishima M, Moriwaki H.
    J Cancer Res Clin Oncol; 2005 Feb 20; 131(2):73-9. PubMed ID: 15503137
    [Abstract] [Full Text] [Related]

  • 11. Soluble interleukin-2 receptor levels in cerebrospinal fluid of patients with acute lymphocytic leukemia or with non-Hodgkin's lymphoma.
    Chang CS, Liu HW, Lin SF, Chen TP.
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 May 20; 22(2):132-7. PubMed ID: 2605973
    [Abstract] [Full Text] [Related]

  • 12. [Serum soluble IL-2 receptor level in patients with sarcoidosis].
    Ina Y, Takada K, Noda M, Satou T, Hashiba H, Miyachi A, Ito S, Iijima N, Yamamoto M.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Mar 20; 29(3):316-21. PubMed ID: 2067152
    [Abstract] [Full Text] [Related]

  • 13. Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.
    Tatsumi M, Sugahara H, Higuchi I, Fukunaga H, Nakamura H, Kanakura Y, Hatazawa J.
    Int J Clin Oncol; 2009 Apr 20; 14(2):150-8. PubMed ID: 19390947
    [Abstract] [Full Text] [Related]

  • 14. Elevated soluble IL-2 receptor levels correlate with tumor bulk of follicular lymphomas with intestinal involvement.
    Iwamuro M, Shinagawa K, Okada H, Takata K, Yoshino T, Yamamoto K.
    Clin Biochem; 2014 Feb 20; 47(3):191-5. PubMed ID: 24362271
    [Abstract] [Full Text] [Related]

  • 15. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
    Ohno H, Ishikawa T, Kitajima H, Nomura S, Suzuki T, Konishi H, Ohno Y, Onishi R, Konaka Y, Arima N, Doi S, Nasu K, Takahashi T, Tsudo M, Fukuhara S, Uchiyama T.
    Rinsho Ketsueki; 2002 Mar 20; 43(3):170-5. PubMed ID: 11979748
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
    Kono N, Kanda Y, Yamamoto R, Chizuka A, Suguro M, Hamaki T, Arai C, Matsuyama T, Takezako N, Miwa A, Togawa A.
    Leuk Lymphoma; 2000 Mar 20; 37(1-2):151-6. PubMed ID: 10721779
    [Abstract] [Full Text] [Related]

  • 17. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Barak V, Ginzburg M, Kalickman I, Polliack A.
    Leuk Lymphoma; 1992 Aug 20; 7(5-6):431-8. PubMed ID: 1493444
    [Abstract] [Full Text] [Related]

  • 18. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M.
    Cancer Res; 1993 May 01; 53(9):2118-22. PubMed ID: 8481913
    [Abstract] [Full Text] [Related]

  • 19. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma.
    Gause A, Roschansky V, Tschiersch A, Smith K, Hasenclever D, Schmits R, Diehl V, Pfreundschuh M.
    Ann Oncol; 1991 Feb 01; 2 Suppl 2():43-7. PubMed ID: 2049320
    [Abstract] [Full Text] [Related]

  • 20. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
    Kandefer-Szerszeń M, Legieć W, Dmoszyńska A, Rzeski W.
    Arch Immunol Ther Exp (Warsz); 1997 Feb 01; 45(5-6):443-8. PubMed ID: 9437500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.